Myeloid‐derived suppressor cells and tumor: Current knowledge and future perspectives

2018 ◽  
Vol 234 (7) ◽  
pp. 9966-9981 ◽  
Author(s):  
Elahe Safari ◽  
Sajjad Ghorghanlu ◽  
Homayoun Ahmadi‐khiavi ◽  
Sahar Mehranfar ◽  
Ramazan Rezaei ◽  
...  
Keyword(s):  
Current Knowledge ◽  
Suppressor Cells ◽  
Myeloid Derived Suppressor Cells ◽  
Future Perspectives

Myeloid-Derived Suppressor Cells in the Tumor Microenvironment: Current Knowledge and Future Perspectives

2017 ◽  
Vol 66 (2) ◽  
pp. 113-123 ◽  
Author(s):  
Maria Ibáñez-Vea ◽  
Miren Zuazo ◽  
Maria Gato ◽  
Hugo Arasanz ◽  
Gonzalo Fernández-Hinojal ◽  
...  
Keyword(s):  
Tumor Microenvironment ◽  
Current Knowledge ◽  
Suppressor Cells ◽  
Myeloid Derived Suppressor Cells ◽  
Future Perspectives

scholarly journals Targeting Myeloid-Derived Suppressor Cells in Ovarian Cancer

Cells ◽  
2021 ◽  
Vol 10 (2) ◽  
pp. 329
Author(s):  
Seiji Mabuchi ◽  
Tomoyuki Sasano ◽  
Naoko Komura
Keyword(s):  
Ovarian Cancer ◽  
Current Knowledge ◽  
Clinical Stage ◽  
Suppressor Cells ◽  
Myeloid Derived Suppressor Cells ◽  
Murine Models ◽  
Inhibitory Effects ◽  
Advanced Clinical Stage ◽  
Growth Inhibitory ◽  
Immature Myeloid Cells

Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells that exhibit immunosuppressive activity. They also directly stimulate tumor cell proliferation, metastasis, and angiogenesis. In ovarian cancer, there are increased numbers of circulating or tumor-infiltrating MDSCs, and increased frequencies of MDSCs are associated with a poor prognosis or an advanced clinical stage. Moreover, in murine models of ovarian cancer, MDSC depletion has shown significant growth-inhibitory effects and enhanced the therapeutic efficacy of existing anticancer therapies. In this review, we summarize the current knowledge on MDSC biology, clinical significance of MDSC, and potential MDSC-targeting strategies in ovarian cancer.

scholarly journals Myeloid-Derived Suppressor Cells in Prostate Cancer: Present Knowledge and Future Perspectives

Cells ◽  
2021 ◽  
Vol 11 (1) ◽  
pp. 20
Author(s):  
Filippos Koinis ◽  
Anastasia Xagara ◽  
Evangelia Chantzara ◽  
Vassiliki Leontopoulou ◽  
Chrissovalantis Aidarinis ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
State Of The Art ◽  
Suppressor Cells ◽  
Immune Checkpoint Blockade ◽  
Present Knowledge ◽  
Myeloid Derived Suppressor Cells ◽  
Future Perspectives ◽  
Tumor Types ◽  
Major Mediator

Several lines of research are being investigated to better understand mechanisms implicated in response or resistance to immune checkpoint blockade in prostate cancer (PCa). Myeloid-derived suppressor cells (MDSCs) have emerged as a major mediator of immunosuppression in the tumor microenvironment that promotes progression of various tumor types. The main mechanisms underlying MDSC-induced immunosuppression are currently being explored and strategies to enhance anti-tumor immune response via MDSC targeting are being tested. However, the role of MDSCs in PCa remains elusive. In this review, we aim to summarize and present the state-of-the-art knowledge on current methodologies to phenotypically and metabolically characterize MDSCs in PCa. We describe how these characteristics may be linked with MDSC function and may influence the clinical outcomes of patients with PCa. Finally, we briefly discuss emerging strategies being employed to therapeutically target MDSCs and potentiate the long-overdue improvement in the efficacy of immunotherapy in patients with PCa.

scholarly journals Myeloid-Derived Suppressor Cells in Infection: A General Overview

2018 ◽  
Vol 10 (5-6) ◽  
pp. 407-413 ◽  
Author(s):  
Eva Medina ◽  
Dominik Hartl
Keyword(s):  
Immune Response ◽  
Inflammatory Responses ◽  
Fungal Infections ◽  
Current Knowledge ◽  
Suppressor Cells ◽  
Myeloid Derived Suppressor Cells ◽  
Chronic Infections ◽  
Initial Infection ◽  
Pathogen Persistence ◽  
Key Players

After initial infection, the immune response that serves to restrict the invading pathogen needs to be tightly calibrated in order to avoid collateral immunopathological damage. This calibration is performed by specialized suppressor mechanisms, which are capable of dampening overwhelming or unremitting inflammation in order to prevent tissue damage. Myeloid-derived suppressor cells (MDSC) are emerging as key players in counter-balancing inflammatory responses and pathogenesis during infection. However, some pathogens are able to exploit the suppressive activities of MDSC to favor pathogen persistence and chronic infections. In this article, we review the current knowledge about the importance of MDSC in the context of bacterial, virus, parasites, and fungal infections.

scholarly journals Myeloid-derived suppressor cells and their role in gynecological malignancies

Tumor Biology ◽  
2018 ◽  
Vol 40 (7) ◽  
pp. 101042831877648 ◽  
Author(s):  
Seiji Mabuchi ◽  
Eriko Yokoi ◽  
Naoko Komura ◽  
Tadashi Kimura
Keyword(s):  
Immune Responses ◽  
Current Knowledge ◽  
Gynecological Cancer ◽  
Suppressor Cells ◽  
Heterogeneous Population ◽  
Cancer Therapies ◽  
Myeloid Derived Suppressor Cells ◽  
Immunosuppressive Activity ◽  
Anti Cancer ◽  
Immature Myeloid Cells

Myeloid-derived suppressor cells are a heterogeneous population of immature myeloid cells that exhibit immunosuppressive activity (they block the proliferation and activity of both T cells and natural killer cells). In addition to their role in suppressing immune responses, myeloid-derived suppressor cells directly stimulate tumor cell proliferation, metastasis, and angiogenesis. In the area of gynecological cancer, increased numbers of circulating myeloid-derived suppressor cells or tumor-infiltrating myeloid-derived suppressor cells have been detected, and the increased frequencies of myeloid-derived suppressor cells are associated with a poor prognosis. Thus, the successful myeloid-derived suppressor cells depletion may hold the key to maximizing existing anti-cancer therapies and improving the prognosis of gynecological cancer. In this review, we summarize current knowledge regarding myeloid-derived suppressor cells biology, clinical significance of myeloid-derived suppressor cells, and the potential myeloid-derived suppressor cells–targeting strategies in gynecological cancer.

scholarly journals Myeloid-Derived Suppressor Cells as a Regulator of Immunity in Organ Transplantation

2018 ◽  
Vol 19 (8) ◽  
pp. 2357 ◽  
Author(s):  
Tsukasa Nakamura ◽  
Hidetaka Ushigome
Keyword(s):  
T Cells ◽  
Organ Transplantation ◽  
Allograft Rejection ◽  
Current Knowledge ◽  
Suppressor Cells ◽  
Regulatory Function ◽  
Myeloid Derived Suppressor Cells ◽  
Killer T Cells ◽  
Shed Light

Regulation of allo-immune responses is proposed as a topic for investigation in the current field of organ transplantation. As a regulator, regulatory T cells (Tregs) have received attention due to their ability to control allograft rejection. Concurrently, however, the independent action of Tregs is not enough to achieve tolerance status in many situations. Meanwhile, as a multi-functional regulator, myeloid-derived suppressor cells (MDSCs) can suppress effector T cells as well as induce Tregs or regulatory B cells (Bregs) in certain circumstances. Furthermore, the importance of a crosstalk between MDSCs and natural killer T cells to induce tolerance has been reported. Thus, orchestration between MDSCs, myeloid regulators, T/Bregs and other lymphoid/myeloid regulators can shed light on achieving allogeneic tolerance. Here, we review the current knowledge in terms of immunological regulatory function displayed by MDSCs in the context of organ transplantation. Ideal control of MDSCs would lead to a reduction of allograft rejection and subsequent long-term allograft acceptance.

Sign in / Sign up

Export Citation Format

Share Document